| Literature DB >> 29288729 |
Jennifer Klump1, Ulrike Phillipp2, Marie Follo2, Anna Eremin1, Hannes Lehmann1, Sigrun Nestel3, Nikolas von Bubnoff2, Irina Nazarenko4.
Abstract
Clinical evidence in oncology argues for the advantages of performing molecular analysis of blood biomarkers to provide information about systemic changes and tumor heterogeneity. Whereas the diagnostic value of cell-free circulating DNA (fcDNA) has successfully been demonstrated in several studies, DNA enclosed in extracellular vesicles (EV) has only recently been described, and its potential diagnostic value is unclear. We established a protocol for separation of EV and fc fractions and tested for presence of mutant BRAFV600E mediating resistance to Vemurafenib and cKITD816V mediating resistance to Imatinib in blood of patients with melanoma and mastocytosis. Our results show that EV contain significantly higher amounts of total DNA as compared to the fc fraction. However, about ten-fold higher copy numbers of the wild type and mutant BRAF and cKIT were detected in the fcDNA fraction supporting its diagnostic value and pointing to differences in fc and EV DNA content.Entities:
Keywords: BRAF; BRAFV600E; Extracellular vesicles; Free-circulating DNA; Liquid biopsy; Predictive biomarkers; Therapy monitoring; cKIT; cKITD816V
Mesh：
Substances：
Year: 2017 PMID： 29288729 DOI： 10.1016/j.nano.2017.12.009
Source DB: PubMed Journal: Nanomedicine ISSN： 1549-9634 Impact factor: 5.307